{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:04:25Z","timestamp":1789761865755,"version":"4.0.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,8,22]],"date-time":"2027-08-22T00:00:00Z","timestamp":1818892800000},"content-version":"am","delay-in-days":325,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K02769"],"award-info":[{"award-number":["25K02769"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.urolonc.2026.07.024","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T10:31:19Z","timestamp":1787394679000},"page":"633-642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A phase-specific benefit\u2013toxicity framework for perioperative trials in muscle-invasive bladder cancer: A focused review andtrial-level mapping analysis"],"prefix":"10.1016","volume":"44","author":[{"given":"Masanao","family":"Shinohara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Hamaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaki","family":"Ichiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teppei","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikara","family":"Ohyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0026-4079","authenticated-orcid":false,"given":"Shingo","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.07.024_bib0001","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.07.024_bib0002","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/iju.15362","article-title":"Summary of the clinical practice guidelines for upper tract urothelial carcinoma 2023 by the Japanese Urological Association","volume":"31","author":"Mori","year":"2024","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2026.07.024_bib0003","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.07.024_bib0004","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1093\/annonc\/mdu126","volume":"25","author":"Kitamura","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2026.07.024_bib0005","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","volume":"79","author":"Pfister","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.07.024_bib0006","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1111\/iju.15561","article-title":"The first detailed annual record on the National Clinical Database Urology Division in Japan: a report on five surgical procedures","volume":"31","author":"Kikuchi","year":"2024","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2026.07.024_bib0007","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/jjco\/hyaf001","article-title":"Optimization of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin therapy for Japanese patients with urothelial carcinoma","volume":"55","author":"Kawai","year":"2025","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.07.024_bib0008","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/iju.70119","article-title":"Early experience with dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin as neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer","volume":"32","author":"Minato","year":"2025","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2026.07.024_bib0009","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/iju.70064","article-title":"Does neoadjuvant chemotherapy followed by radical cystectomy improve the survival of muscle-invasive bladder cancer in real-world clinical practice?","volume":"32","author":"Naito","year":"2025","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2026.07.024_bib0010","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.71109","article-title":"Safety of robot-assisted radical cystectomy for muscle-invasive bladder cancer: a real-world analysis using the national clinical database in Japan","volume":"14","author":"Hatakeyama","year":"2025","journal-title":"Cancer Med"},{"key":"10.1016\/j.urolonc.2026.07.024_bib0011","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.urolonc.2025.08.014","article-title":"Comparison of adjuvant and neoadjuvant therapies for muscle invasive bladder cancer: a network meta-analysis","volume":"44","author":"Petrelli","year":"2026","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.07.024_bib0012","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.euros.2026.04.011","article-title":"Real-world outcomes of adjuvant nivolumab in high-risk bladder and upper tract urothelial carcinoma after radical surgery","volume":"88","author":"Tazawa","year":"2026","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.urolonc.2026.07.024_bib0013","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-11319-w","article-title":"Trends in the use and efficacy of adjuvant immunotherapy in muscle-invasive urothelial carcinoma","volume":"15","author":"Hatakeyama","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2026.07.024_bib0014","doi-asserted-by":"crossref","DOI":"10.1111\/iju.70283","article-title":"Prognostic significance of achieving the radical cystectomy-pentafecta after neoadjuvant chemotherapy and robot-assisted radical cystectomy","volume":"33","author":"Fukuta","year":"2026","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2026.07.024_bib0015","doi-asserted-by":"crossref","DOI":"10.1111\/iju.70450","article-title":"Real-world outcomes after radical cystectomy for muscle-invasive bladder cancer in Japan: a nationwide descriptive study from the national clinical database","volume":"33","author":"Hatakeyama","year":"2026","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2026.07.024_bib0016","doi-asserted-by":"crossref","DOI":"10.1111\/iju.70314","article-title":"Real-world comparison of survival outcomes between RC and intravesical Bacillus Calmette-Gu\u00e9rin (BCG) therapy in BCG-na\u00efve or -unresponsive non-muscle-invasive bladder cancer","volume":"33","author":"Miyake","year":"2026","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2026.07.024_bib0017","doi-asserted-by":"crossref","DOI":"10.1111\/iju.70316","article-title":"Reconsidering the role of 12-month recurrence in the radical cystectomy-pentafecta metric","volume":"33","author":"Urabe","year":"2026","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2026.07.024_bib0018","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \"unfit\" for Cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.07.024_bib0019","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.07.024_bib0020","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/jjco\/hyag027","article-title":"Clinical impact of carboplatin-based neoadjuvant chemotherapy: lack of benefit and surgical delay in muscle-invasive bladder cancer","volume":"56","author":"Kato","year":"2026","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.07.024_bib0021","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70782","article-title":"Effects of the number of neoadjuvant cycles and addition of adjuvant chemotherapy on the prognosis of muscle-invasive bladder cancer treated with radical cystectomy","volume":"14","author":"Hatakeyama","year":"2025","journal-title":"Cancer Med"},{"key":"10.1016\/j.urolonc.2026.07.024_bib0022","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/iju.70122","article-title":"PD-L1 and Ki-67 expression before and after neoadjuvant chemotherapy in muscle-invasive bladder cancer","volume":"32","author":"Sasaki","year":"2025","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2026.07.024_bib0023","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/jjco\/hyaf218","article-title":"Age-stratified outcomes of radical cystectomy for muscle-invasive bladder cancer: a nationwide multicenter study of 1867 patients in Japan","volume":"56","author":"Kawai","year":"2026","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.07.024_bib0024","article-title":"Real-world comparison of neoadjuvant chemoimmunotherapy and chemotherapy in muscle-invasive bladder cancer","volume":"15","author":"Ding","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2026.07.024_bib0025","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.euros.2025.07.010","article-title":"Neoadjuvant immunotherapy in bladder cancer: ushering in a new era of treatment-A systematic review of current evidence","volume":"79","author":"Suartz","year":"2025","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.urolonc.2026.07.024_bib0026","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"7_suppl","key":"10.1016\/j.urolonc.2026.07.024_bib0027","doi-asserted-by":"crossref","first-page":"LBA630","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA630","article-title":"Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: randomized, open-label, phase 3 KEYNOTE-B15 study","volume":"44","author":"Galsky","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.07.024_bib0028","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1056\/NEJMoa2511674","article-title":"Perioperative enfortumab vedotin and pembrolizumab in bladder cancer","volume":"394","author":"Vulsteke","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.07.024_bib0029","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.07.024_bib0030","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/1471-2288-12-173","article-title":"A framework for organizing and selecting quantitative approaches for benefit-harm assessment","volume":"12","author":"Puhan","year":"2012","journal-title":"BMC Med Res Methodol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926006186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926006186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:12:13Z","timestamp":1789758733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926006186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1078143926006186"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.07.024","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase-specific benefit\u2013toxicity framework for perioperative trials in muscle-invasive bladder cancer: A focused review andtrial-level mapping analysis","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.07.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}